Abstract
Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the development of biologic therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention with fewer side effects than traditional therapies. The goal of this article is to review the progress of the biologic agents which are available, or under investigation for clinical use: infliximab, etanercept, efalizumab, alefacept, and adalimumab. In addition, two other investigational therapies, oral tazarotene and oral pimecrolimus will be discussed. Clinical data for these agents, including the most recent phase II and / or III study results, will be discussed, as well as the most recent safety data
Keywords: psoriasis, biologic therapy, t cell, cytokine, infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene
Current Pharmaceutical Design
Title: Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Volume: 11 Issue: 2
Author(s): Ritu Saini, William D. Tutrone and Jeffrey M. Weinberg
Affiliation:
Keywords: psoriasis, biologic therapy, t cell, cytokine, infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene
Abstract: Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the development of biologic therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention with fewer side effects than traditional therapies. The goal of this article is to review the progress of the biologic agents which are available, or under investigation for clinical use: infliximab, etanercept, efalizumab, alefacept, and adalimumab. In addition, two other investigational therapies, oral tazarotene and oral pimecrolimus will be discussed. Clinical data for these agents, including the most recent phase II and / or III study results, will be discussed, as well as the most recent safety data
Export Options
About this article
Cite this article as:
Saini Ritu, Tutrone D. William and Weinberg M. Jeffrey, Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus, Current Pharmaceutical Design 2005; 11 (2) . https://dx.doi.org/10.2174/1381612053382232
DOI https://dx.doi.org/10.2174/1381612053382232 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epidemiology of Septic Acute Kidney Injury
Current Drug Targets New Antipsychotics in Treatment of Mood Instability and Cognitive Perceptual Symptoms in Borderline Personality Disorder
Current Psychopharmacology Editorial: [Hot Topic: Chromogranin A at the Crossroads of Health and Disease]
Current Medicinal Chemistry Regioselective Synthesis of Novel Fused Sulphonamide Derivatives Utilizing Microwave Irradiation
Current Microwave Chemistry Brain Perfusion In Sepsis
Current Vascular Pharmacology Therapeutic Interventions in the Glyc(oxid)ation Pathway
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Native Proteins in Organic Chemistry. Recent Achievements in the use of non Hydrolytic Enzymes for the Synthesis of Pharmaceuticals
Current Organic Chemistry Influence of a Novel Inhibitor (UM8190) of Prolylcarboxypeptidase (PRCP) on Appetite and Thrombosis
Current Medicinal Chemistry Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Current Genomics Cardioprotective effects of Aronia melanocarpa anthocynanins. From laboratory experiments to clinical practice.
Current Pharmaceutical Design Preface [Hot Topic: Exogenous Factors Affecting Cardiovascular and Hematological Targets (Guest Editor: R. Manjunatha Kini)]
Current Drug Targets - Cardiovascular & Hematological Disorders The Role of NPY and Ghrelin in Anorexia Nervosa
Current Pharmaceutical Design Adverse Drug Reactions in a Pulmonary Teaching Hospital: Incidence, Pattern, Seriousness, and Preventability
Current Drug Safety Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Pyrazolo-Triazolo-Pyrimidine Derivatives as Adenosine Receptor Antagonists: A Possible Template for Adenosine Receptor Subtypes?
Current Pharmaceutical Design Epidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Current Alzheimer Research The Vernakalant Story: How Did It Come to Approval in Europe and What is the Delay in the U.S.A?
Current Cardiology Reviews Peripartum Cardiomyopathy: An Intriguing Challenge. Case Report with Literature Review
Current Cardiology Reviews Therapeutic Angiogenesis in Ischemic Heart Disease: Gene or Recombinant Vascular Growth Factor Protein Therapy?
Current Gene Therapy